1. Introduction
===============

Previous studies have shown that the degree of carotid artery stenosis is a biological indicator to evaluate the occurrence of stroke events.^\[[@R1]\]^ Subsequent studies have demonstrated that the components of carotid atherosclerotic plaques that contribute to carotid artery stenosis can be well detected by magnetic resonance imaging (MRI) and also used as a tool for predicting and assessing stroke risk.^\[[@R2],[@R3]\]^ Meanwhile, carotid endarterectomy (CEA), as a secondary intervention measure for stroke, plays an important role in preventing future stroke.^\[[@R4]\]^ However, the risk--benefit ratio of carotid endarterectomy for low-risk patients with carotid atherosclerotic plaque remains to be determined.^\[[@R5]\]^ Nevertheless, CEA treatment may be helpful for some patients with less severe carotid artery stenosis with the characteristics of plaque vulnerability.^\[[@R6]\]^ Therefore, whether patients with symptomatic carotid plaque need CEA to prevent recurrence of stroke events is very important for whether patients need to bear the risks and treatment costs brought by the surgery. The components of carotid artery plaque, such as thinned or ruptured fibrous caps (TRFC), lipid-rich/necrotic cores (LRNC), and intraplaque hemorrhage (IPH), etc., as biomarkers for predicting the first occurrence of stroke,^\[[@R7]\]^ whether they can continue to be used as tools for predicting and evaluating the risk of recurrence of stroke events needs to be further confirmed. However, recent studies have shown that IPH, TRFC, and LRNC can be used as biological indicators to predict recurrent cerebral ischemic events.^\[[@R5],[@R8],[@R9]\]^ Therefore, we plan to conduct a systematic review and meta-analysis to further confirm whether the components of carotid artery plaque can be used as an independent biological indicator to predict and evaluate the risk of stroke recurrence.

2. Methods
==========

2.1. Study registration
-----------------------

The protocol has been registered in the International Prospective Register of Systematic Reviews (PROSPERO) with registration number CRD42019124043 on February 19, 2019.

2.2. Ethics and dissemination
-----------------------------

The protocol of this systematic review will be disseminated in a peer reviewed journal and presented at relevant conferences. It is not necessary for a formal ethical approval, because the data are not individualized.

2.3. Inclusion criteria for study selection
-------------------------------------------

### 2.3.1. Types of studies

We will include cohort studies, with language limited to English. Specific inclusion criteria were: English language articles; MRI of carotid vessel plaque composition; mean follow-up \>1 month; assessment for development of recurrent ipsilateral stroke or recurrent TIA; prospective cohort study. The exclusion criteria were: articles without specific data provided; case reports and reviews were excluded. This systematic review and meta-analysis is an evaluation study on the characteristic components of carotid artery plaque and the risk of recurrent stroke events, which does not involve the accuracy test of MRI sequence diagnosis or the study on the histopathology of carotid artery plaque. We included 3 specific plaque elements in this study: IPH; LRNC; and TRFC.

### 2.3.2. Types of participants

Patients in the included study were adults and had prior cerebral ischemic symptoms, including hemispheric transient ischemic attack, amaurosis fugax, or non-disabling stroke, and were followed up for at least 1 month, all of which were confirmed by the study center, experienced physicians, or clinical consultants. Regardless of the recurrence of cerebral ischemic events, all patients received MRI scans of carotid artery plaques before or after the second intervention.

2.4. Search methods for the identification of studies
-----------------------------------------------------

### 2.4.1. Electronic searches

Electronic search will be performed in PUBMED, EMBASE, Cochrane Controlled Register of Trials (CENTRAL) from inception to Oct 30, 2018. We will use the Mesh terms and keywords in combination: carotid artery, carotid plaque, atherosclerosis, stroke, recurrent, recurrence, ischemic events. The search strategy for PubMed is shown in Table [1](#T1){ref-type="table"}.
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Search strategy used in PubMed.
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### 2.4.2. Searching other resources

The reference list of previously published systematic reviews focusing on predicting the risk of stroke and eligible studies will be searched. We will manually retrieve conference proceedings and academic exchange summaries.

2.5. Data collection and analysis
---------------------------------

### 2.5.1. Selection of studies

Before the search begins, each reviewer will receive professional training to ensure consistency in the selection process and avoid the risk of bias (ROB) in human factors. The screening process will use EndNote X8 literature management software. The 2 review authors will read the topics, abstracts, keywords, and the full text independently if needed. The screening process will be strictly in accordance with the inclusion criteria. If there is a disagreement, it will be decided with another reviewer. We will record the exclusion reason for the excluded literature. The details of selection process will be shown in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart (Fig. [1](#F1){ref-type="fig"}).
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### 2.5.2. Data extraction and management

Two reviewers will extract information from eligible studies using a predefined data extraction form. We will include the needed information via 4 parts:

Characteristics of the included trials: the first author, year of publication, study design, total sample size; characteristics of participants: age (mean age), sex (male, %), number of medically managed participants, number of carotid arteries with follow-up outcome data, disease severity (mean degree of arterial stenosis), hypertension, diabetes, smoking, diabetes mellitus, type of symptom on presentation, ipsilateral recurrent strokes in negative test group, ipsilateral recurrent strokes in positive test group, time from presenting symptom and MRI, the mean time interval between the second MR scan and the recurrent event, number of arteries with negative MRI, number of arteries with positive MRI, ipsilateral all ischemic events in negative or positive test group; characteristics of MRI scan: parameters of MRI scan, scan sequence; characteristics of outcome: imaging of plaque elements, all ischemic event HR, 95% CI.

2.6. Risk of bias assessment
----------------------------

We plan to use the Newcastle-Ottawa Scale for assessing risk of bias which mainly includes 4 specific domains: trials population selection, comparability between groups, the results of evaluation or evaluation of exposure factors. Methodological quality will be considered as low risk, high risk, or unclear risk of bias. Two reviewers will complete the easement of risk of bias, disputes shall be settled through discussion, or a third party shall participate in judgment and arbitration.

2.7. Data synthesis
-------------------

RevMan 5.3 (Review Manager (RevMan) \[Computer program\]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014) software provided by Cochrane collaboration ([www.cochrane.org](http://www.cochrane.org/)) will be used to conduct meta-analysis and synthesis. The HR, a potentially more useful measure of risk taking into account time to events, can be more significant for our systematic meta-analysis. The HR that demonstrating relationship between IPH, LRNC, and TRFC and the risk of recurrent ischemic events (Stroke plus TIA) and 95% confidence interval (95% CI) will be detected, respectively, for each specific plaque element.

2.8. Quality of evidence assessment
-----------------------------------

The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) will be used as a tool for assessing the strength of the body of evidence. According to the GRADE evidence evaluation system, the level strength of evidence can be divided into the following 4 levels: high, moderate, low, or very low.

2.9. Heterogeneity assessment
-----------------------------

Heterogeneity between studies will be evaluated by using the Cochrane *Q* test (*P* \< 0.10 will be defined as statistically significant heterogeneity), and it will be quantified with *I*^2^ statistics (heterogeneity will be considered as low, moderate, large, and very large for *I*^2^ \<25%, 25%--49%, 50%--74%, and ≥75%, respectively). When there is very large heterogeneity between studies, we will run meta-regression to locate the source of heterogeneity and perform subgroup analysis.

2.10. Assessment of reporting bias
----------------------------------

Egger test will be used to assess the publication bias and the small study biases. When a *P*-value \<.10 in the regression asymmetry is found, we will consider the existence of small-study effect.

2.11. Meta-analysis
-------------------

Meta-analysis will be performed by using RevMan (Review Manager, version 5.3). The HRs of the included studies will be combined by using both fixed-effects model and random-effects model, and we will check the consistency of the results between the 2 models. When *I*^2^ \<50%, we will report the result generated by the fixed-effects model; otherwise, we will choose the result by the random-effects model.

2.12. Sensitivity analysis
--------------------------

We will perform the following sensitivity analyses: excluding studies with high or unclear risk of bias; excluding studies with total sample size \<50 participants; excluding studies with significant small-study effect.

2.13. Meta-regression and subgroup analysis
-------------------------------------------

If there is a significant heterogeneity in the included trials, subgroup analysis based on treatment, parameters of MRI scan, stenosis degree, and other potential factors will be performed to explore the possible factors of heterogeneity.

2.14. Publication bias
----------------------

Egger test will be used to assess the publication bias and the small study bias. When a *P*-value \<.10 in the regression asymmetry is found, we will consider the existence of small-study effect. However, if there are \<10 articles included, publication bias will not be explored.

2.15. Trial sequential analysis
-------------------------------

Meta-analysis may generate false-positive findings (type I error) because of repeated significance testing. To assess the risk of type I error, we will apply trial sequential analysis (TSA), which estimates the information size (cumulated sample size of the included studies) and adjusts threshold for statistical significance (TSA software, version 0.9 beta).

3. Discussion
=============

The main components of carotid artery plaque are IPH, LRNC, TRFC.^\[[@R3]\]^ A large number of histopathological studies and prospective studies have confirmed that IPH, LRNC, and TRFC are unstable factors of the arterial plaque and stimulate the plaque progression.^\[[@R10],[@R11]\]^ At the same time, these plaque components can be evaluated noninvasively by MRI.^\[[@R7],[@R12]--[@R16]\]^ MRI features of carotid artery plaques can assess the risk of ipsilateral ischemic events, which has been confirmed by a systematic review and meta-analysis.^\[[@R17]\]^ Patients with symptomatic severe carotid artery stenosis have a decreased risk of recurrence of cerebral ischemic events after CEA surgery.^\[[@R18]\]^ However, the using of carotid stenosis to assess carotid endarterectomy is considered imperfect, which determining the risk of recurrence in some patients remains difficult.^\[[@R19],[@R20]\]^ Recent studies have shown that carotid artery plaque components detected by Magnetic resonance technique can be used not only as biomarkers to assess the risk of ipsilateral stroke, but also to assess the risk of recurrent stroke or recurrent ischemic events. This provides evidence for defining the risk of recurrent stroke or ischemic events in patients with symptomatic carotid plaque. To our knowledge, there is no related systematic review evaluating the association between carotid plaque characteristics and recurrent stroke or recurrent ischemic events. Therefore, we will conduct a systematic review and meta-analysis to assess the association between MRI features of carotid artery plaques and recurrent stroke or recurrent ischemic events. Our aim is to provide reliable evidence to help clinicians make decisions selecting patient selection for CEA surgery.
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